Class-action accuses Takeda of ‘pay-for-delay’ deal with Par

Takeda Pharmaceuticals organised a pay-for-delay deal with Par Pharmaceuticals to prevent a generic version of its constipation treatment from releasing, according to a complaint submitted to the US District Court for the District of Massachusetts.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

AstraZeneca and Takeda enter agreement to develop Parkinson’s disease drug

29 August 2017 AstraZeneca and Takeda have entered into an agreement to develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease.

Big Pharma

EUIPO sides with Takeda in trademark appeal

28 November 2018 Japan-based Takeda Pharmaceutical has persuaded the European Union Intellectual Property Office that an applied-for trademark would be confused with its own earlier-registered mark

Americas

Takeda, Arbor aim to stop Turkish copies of high blood pressure drug

22 March 2022 Takeda Pharmaceutical and Arbor Pharmaceuticals are seeking to block Turkey-based EastPharma from releasing a generic version of the blockbuster high blood pressure medication, Edarbi.

More on this story

Asia

AstraZeneca and Takeda enter agreement to develop Parkinson’s disease drug

Big Pharma

EUIPO sides with Takeda in trademark appeal

28 November 2018 Japan-based Takeda Pharmaceutical has persuaded the European Union Intellectual Property Office that an applied-for trademark would be confused with its own earlier-registered mark

Americas

Takeda, Arbor aim to stop Turkish copies of high blood pressure drug

22 March 2022 Takeda Pharmaceutical and Arbor Pharmaceuticals are seeking to block Turkey-based EastPharma from releasing a generic version of the blockbuster high blood pressure medication, Edarbi.

More on this story

Asia

AstraZeneca and Takeda enter agreement to develop Parkinson’s disease drug

Big Pharma

EUIPO sides with Takeda in trademark appeal

28 November 2018 Japan-based Takeda Pharmaceutical has persuaded the European Union Intellectual Property Office that an applied-for trademark would be confused with its own earlier-registered mark

Americas

Takeda, Arbor aim to stop Turkish copies of high blood pressure drug

22 March 2022 Takeda Pharmaceutical and Arbor Pharmaceuticals are seeking to block Turkey-based EastPharma from releasing a generic version of the blockbuster high blood pressure medication, Edarbi.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent

Class-action accuses Takeda of ‘pay-for-delay’ deal with Par

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features